Arthneeti
Latest: Amanta Healthcare Ltd Q1 FY27 results →All Q3 FY26 results →
AH

Amanta Healthcare Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Amanta Healthcare Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Price₹196
Market cap₹607 Cr
P/E39.6
Updated23 Aug 2026
Read4 min read

Amanta Healthcare Ltd Q3 FY26 key numbers

Revenue
Revenue expected to reach approximately INR400 crores by March 2027, implying about 33% growth next year.

As stated in Amanta Healthcare Ltd's Q3 FY26 earnings call transcript · published 16 Jul 2026. Reported figures, not investment advice.

The short version

Revenue expected to reach approximately INR400 crores by March 2027, implying about 33% growth next year. Revenue is expected to grow roughly 33% in FY’27, reaching around INR400 crores, primarily driven by SteriPort expansion.

From Amanta Healthcare Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Revenue expected to reach approximately INR400 crores by March 2027, implying about 33% growth next year.
  • SteriPort incremental revenue projected around INR120 crores post-expansion.
  • SVP expansion to add roughly INR30 crores incremental revenue, commissioning expected by January 2027, though full value creation will take 1-2 years due to regulatory approvals and product ramp-up.
  • 20%+ CAGR growth rate anticipated over the next two years.
  • Post-expansion, significant scale-up in production with output reaching full capacity quickly, with inventory normalization expected within 6-9 months.

2 more points from Amanta Healthcare Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Amanta Healthcare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Ongoing expansion initiated prior to IPO, combining two phases into one, started in 2024.
  • Manufacturing equipment and utilities are being installed; expected commissioning by mid-March 2026.
  • Commercial production for SteriPort line anticipated by April 2026, with full ramp-up taking 6-9 months.
  • Incremental SteriPort revenue expected around INR120 crores; combined with SVP line, total incremental revenue approximately INR150 crores.
  • SVP expansion planned to commission by January 2027, focusing on inhalation solutions (respules), with a 1-2 year ramp-up for value addition and approvals.
  • Capex funded through IPO proceeds; post-expansion, capex levels expected to significantly reduce.

2 more points from Amanta Healthcare Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Amanta Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The discussion focuses primarily on: - Working capital and cash position - Debt repayment plans and current debt levels - Revenue and expansion projections, especially related to SteriPort and SVP product lines

2 more points from Amanta Healthcare Ltd's call on order book

Create a free account to keep reading this call

Amanta Healthcare Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹77 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Amanta Healthcare Ltd's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Amanta Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Amanta Healthcare Ltd Q3 FY26 results?

Revenue expected to reach approximately INR400 crores by March 2027, implying about 33% growth next year. Revenue is expected to grow roughly 33% in FY’27, reaching around INR400 crores, primarily driven by SteriPort expansion.

What is Amanta Healthcare Ltd share price analysis?

Amanta Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 39.6 with a market cap of ₹607 Cr. Investors should review the full earnings analysis for detailed insights.

Is Amanta Healthcare Ltd planning capital expenditure?

Ongoing expansion initiated prior to IPO, combining two phases into one, started in 2024.

Keep Amanta Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.